Hypersensitivity. Patients who had MI, ischaemic heart disease, Prinzmetal's angina, coronary vasospasm, peripheral vascular disease or those who have symptoms or signs consistent w/ ischaemic heart disease; w/ history of CVA or transient ischaemic attack (TIA). Patients w/ moderate, severe & uncontrolled HTN. Concomitant use w/ ergotamine derivatives or ergotamine (including methysergide) &/or any triptan (5-HT
1) receptor agonists. Severe renal (CrCl <15 mL/min) & hepatic (Child-Pugh grade C) impairment.